Ginkgo acquires machine learning biotech Patch Biosciences

Business acquisition

Ginkgo Bioworks has acquired Patch Biosciences, with the intention to strengthen its gene therapy services, cell therapy services, and RNA therapeutics services. 

Ginkgo provides R&D services across industries, including in biopharma, and will incorporate Patch’s machine learning models and downstream assays into its existing platform, making new capabilities in synthetic promoter and untranslated region (UTR) engineering available to partners.  

Additionally, Patch’s validated muscle promoters and robust RNA UTRs complement Ginkgo’s circular RNA and promoter screening platform technology.   

Jason Kelly, CEO and co-founder of Ginkgo Bioworks: “We want to bring a unified R&D experience to our customers and offering integrated services that include specialised assets like Patch’s allow our customers to tap into a broader-than-ever capability set.” 

Strategic partnership 

This move follows Ginkgo’s collaborations with Pfizer, based around the discovery of RNA-based drug candidates, with the aim of achieving efficient production, circularisation, improved stability, and enhanced translation of each RNA construct. Ginkgo is also working with Sensible Biotechnologies to develop an in vivo microbial mRNA manufacturing platform.  

Additionally, Ginkgo announced the successful completion of a manufacturing optimisation program with Biogen, focused on redefining the industry standard for manufacturing recombinant adeno-associated virus (AAV)-based vectors. The collaboration achieved its goals of enhancing the AAV production titres of Biogen’s gene therapy manufacturing processes.

The addition of Patch’s assets can help Ginkgo further expand its pipeline of gene therapy, cell therapy, and RNA programmes and has the potential to immediately accelerate progress on current programmes. 

JB Michel, CEO and co-founder of Patch Biosciences: “Joining Ginkgo Bioworks represents an exciting step in our journey to engineer better genetic medicines. The shared vision and unique expertise of both teams can unlock new frontiers in programmable medicines, which we see as the future of medicine. We are excited to contribute our AI/ML capabilities to the impressive Ginkgo platform, and look forward to engineering better genetic medicines for Ginkgo’s customers in RNA therapeutics, gene therapy, and beyond.” 

Megan Thomas, Multimedia Editor, DDW

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free